Trilo Therapeutics develops Trilomer® peptide-drug conjugates using 100% D-amino acids to achieve rapid tumor penetration and targeted delivery of chemotherapy drugs while minimizing systemic toxicity. This technology addresses the limitations of traditional antibody-drug conjugates by preventing premature drug release and reducing renal uptake, enhancing the therapeutic index for cancer treatment.
Funding
$1.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often exhibit limited tumor penetration, premature drug release, and significant renal uptake, leading to systemic toxicity and reduced therapeutic efficacy in cancer treatment. Current peptide-drug conjugates also face challenges related to protease degradation and renal clearance, hindering their ability to selectively target and eliminate cancer cells.
Solution
Trilo Therapeutics is developing a novel class of cancer therapeutics called Trilomer® peptide-drug conjugates. These conjugates utilize 100% D-amino acids, which are resistant to proteases and exhibit low renal uptake, to achieve rapid tumor penetration and targeted delivery of chemotherapy drugs. The Trilomer® platform overcomes the limitations of traditional ADCs and peptide-drug conjugates by preventing premature drug release and reducing toxicity to healthy tissues. This approach enhances the therapeutic index, allowing for more effective cancer treatment with fewer side effects. The fully synthetic nature of Trilomers® also enables rapid affinity optimization and structure-activity relationship (SAR) studies, accelerating the drug discovery process.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing innovative cancer therapies with improved efficacy and reduced toxicity profiles.
Features
- Composed of 100% D-amino acids for protease resistance and reduced renal uptake
- Rapid tumor penetration due to small size (<6 kDa for bivalent binder plus payload)
- Targeted delivery of chemotherapy drugs or radionuclides to cancer cells
- Bivalent and biparatopic formats for rapid internalization and intracellular drug release
- Non-immunogenic, minimizing the risk of anti-drug antibodies
- DNA-encoded library technology for screening billions of drug candidates
- Compatible with non-natural side chains and beta-amino acids
- Can be mono-, bi-, or tri-cyclized, including head-to-tail amide cyclization